

23 **Abstract**

24 **Background:** *In vitro* transcription (IVT) reactions used to generate nucleoside modified
25 RNA (modRNA) for SARS-CoV-2 vaccines currently rely on an RNA polymerase
26 transcribing from a DNA template. Production of modRNA used in the original Pfizer
27 randomized clinical trial (RCT) utilized a PCR-generated DNA template (Process 1). To
28 generate billions of vaccine doses, this DNA was cloned into a bacterial plasmid vector
29 for amplification in *Escherichia coli* before linearization (Process 2), expanding the size
30 and complexity of potential residual DNA and introducing sequences not present in the
31 Process 1 template. It appears that Moderna used a similar plasmid-based process for
32 both clinical trial and post-trial use vaccines. Recently, DNA sequencing studies have
33 revealed this plasmid DNA at significant levels in both Pfizer-BioNTech and Moderna
34 modRNA vaccines. These studies surveyed a limited number of lots and questions remain
35 regarding the variance in residual DNA observed internationally.

36 **Methods:** Using previously published primer and probe sequences, quantitative
37 polymerase chain reaction (qPCR) and Qubit® fluorometry was performed on an
38 additional 27 mRNA vials obtained in Canada and drawn from 12 unique lots (5 lots of
39 Moderna child/adult monovalent, 1 lot of Moderna adult bivalent BA.4/5, 1 lot of Moderna
40 child/adult bivalent BA.1, 1 lot of Moderna XBB.1.5 monovalent, 3 lots of Pfizer adult
41 monovalent, and 1 lot of Pfizer adult bivalent BA.4/5). The Vaccine Adverse Events
42 Reporting System (VAERS) database was queried for the number and categorization of
43 adverse events (AEs) reported for each of the lots tested. The content of one previously
44 studied vial of Pfizer COVID-19 vaccine was examined by Oxford Nanopore sequencing
45 to determine the size distribution of DNA fragments. This sample was also used to
46 determine if the residual DNA is packaged in the lipid nanoparticles (LNPs) and thus
47 resistant to DNaseI or if the DNA resides outside of the LNP and is DNaseI labile.

48 **Results:** Quantification cycle (Cq) values (1:10 dilution) for the plasmid origin of
49 replication (*ori*) and spike sequences ranged from 18.44 - 24.87 and 18.03 - 23.83 and
50 for Pfizer, and 22.52 – 24.53 and 25.24 – 30.10 for Moderna, respectively. These values
51 correspond to 0.28 – 4.27 ng/dose and 0.22 - 2.43 ng/dose (Pfizer), and 0.01 -0.34
52 ng/dose and 0.25 – 0.78 ng/dose (Moderna), for *ori* and spike respectively measured by
53 qPCR, and 1,896 – 3,720 ng/dose and 3,270 – 5,100 ng/dose measured by Qubit®
54 fluorometry for Pfizer and Moderna, respectfully. The SV40 promoter-enhancer-*ori* was
55 only detected in Pfizer vials with Cq scores ranging from 16.64 – 22.59. In an exploratory
56 analysis, we found preliminary evidence of a dose response relationship of the amount of
57 DNA per dose and the frequency of serious adverse events (SAEs). This relationship was
58 different for the Pfizer and Moderna products. Size distribution analysis found mean and
59 maximum DNA fragment lengths of 214 base pairs (bp) and 3.5 kb, respectively. The
60 plasmid DNA is likely inside the LNPs and is protected from nucleases.

61 **Conclusion:** These data demonstrate the presence of billions to hundreds of billions of
62 DNA molecules per dose in these vaccines. Using fluorometry, all vaccines exceed the
63 guidelines for residual DNA set by FDA and WHO of 10 ng/dose by 188 – 509-fold.
64 However, qPCR residual DNA content in all vaccines were below these guidelines
65 emphasizing the importance of methodological clarity and consistency when interpreting
66 quantitative guidelines. The preliminary evidence of a dose-response effect of residual
67 DNA measured with qPCR and SAEs warrant confirmation and further investigation. Our
68 findings extend existing concerns about vaccine safety and call into question the
69 relevance of guidelines conceived before the introduction of efficient transfection using
70 LNPs. With several obvious limitations, we urge that our work is replicated under forensic
71 conditions and that guidelines be revised to account for highly efficient DNA transfection
72 and cumulative dosing.

73 **Introduction**

74 To produce large amounts of modified RNA (modRNA) vaccine for generalized use, Pfizer
75 changed its manufacturing process (Process 1) used to produce material for the
76 randomized clinical trial (RCT)¹ to a process (Process 2) similar to the one already being
77 used by Moderna. The SARS-CoV-2 spike sequence was cloned into a plasmid
78 containing a bacterial origin of replication (generically termed *ori*) active in *Escherichia*
79 *coli*. This plasmid (7,824 base pairs (bp) and 6,777 bp for Pfizer and Moderna,
80 respectively) also contains an aminoglycoside phosphotransferase gene (*Neo/Kan*) that
81 allows cost effective bacterial replication in a broth containing kanamycin and a doubling
82 of plasmid copy number every 30 minutes at 37°C. The *E. coli* cells are then harvested
83 and lysed. DNA is extracted and linearized with the restriction enzyme *Eam1104I*. This
84 linear DNA then acts as the template for T7 RNA Polymerase *in vitro* transcription (IVT)
85 in the presence of N1-methyl-pseudouridine. After the IVT, DNA is hydrolyzed, reducing
86 its prevalence in the final drug product. Documents leaked from the European Medicines
87 Agency (EMA) and cited in the British Medical Journal² noted that residual DNA in
88 modRNA products made by this process could vary significantly³.

89
90 McKernan *et al.* performed next-generation RNA sequencing of these vaccines and,
91 unexpectedly, found evidence of DNA derived from the expression plasmids used during
92 manufacturing.⁴ McKernan *et al.* then developed a quantitative polymerase chain reaction
93 (qPCR) method towards the DNA contamination with primers targeting shared sequences
94 in both Pfizer and Moderna vaccines.⁴ Additionally, McKernan *et al.*, found SV40
95 promoter-enhancer-*ori*, and SV40 polyA signal sequences in the Pfizer vaccines. To
96 investigate the generalizability of these findings to other lots of vaccines, we obtained 24
97 unopened expired vials (8 Pfizer and 16 Moderna) and three vials of in-date remnants of
98 Moderna XBB.1.5 COVID-19 vaccines that had been distributed in Ontario, Canada and
99 examined them via Qubit[®] fluorometry and qPCR targeting spike, plasmid *ori*, and the
100 SV40 promoter-enhancer-*ori*. We then queried the Vaccine Adverse Event Reporting
101 System (VAERS) for any adverse events (AEs), including serious AEs (SAEs), associated
102 with these lots.⁵ We also extended the observations of an earlier work (McKernan *et al.*⁴)

103 by studying the size distribution of DNA fragments as well as the DNaseI sensitivity of the
104 vaccine to determine whether the residual DNA is packaged in the LNPs.

105
106 For the purpose of this study, we are using the terms "residual DNA," "DNA mass," (or
107 similar) rather than "impurity" or "contamination" as a discussion of these regulatory terms
108 is beyond the scope of this paper.


109

110 **Methods**

111

112 ***COVID-19 Vaccines Tested***

113 Expired unopened vials of Pfizer-BioNTech BNT162b2 (n=8) and Moderna Spikevax
114 mRNA-1273 (n=16) were obtained from various pharmacies in Ontario, Canada (Figure
115 1). Three vials of in-date remnants of the same lot of Moderna XBB.1.5 vaccine were also
116 obtained. In total, 12 lots were surveyed across 27 mRNA vials: 5 lots of Moderna
117 child/adult monovalent, 1 lot of Moderna adult bivalent BA.4/5, 1 lot of Moderna child/adult
118 bivalent Wuhan-BA.1, 1 lot of Moderna XBB.1.5 monovalent, 3 lots of Pfizer adult
119 monovalent, and 1 lot of Pfizer adult bivalent Wuhan-BA.4/5 vaccines. An unopened
120 sterile injectable vial of alprostadil 66 mcg/mL in combination with papaverine 21.7mg/mL
121 and phentolamine 1 mg/mL (TriMix) was used as the negative control. The unopened
122 vials were untampered as they had intact flip-off plastic caps with printed lot numbers and
123 expiration dates. Vials had been stored in a purpose-built vaccine unit at +2-8°C in the
124 pharmacies and were transported in insulated containers with frozen gel packs and
125 placed in the testing laboratory fridge within 5 hours. Only one Moderna vial did not have
126 a printed expiration date but had a QR code that required scanning by a pharmacist. The
127 Moderna XBB.1.5 vials were similarly stored by the pharmacy. Vials were removed from
128 the refrigerator, warmed for ~20 minutes, and administered by the pharmacist to patients
129 over ~30 minutes. The remnant vials were placed in an insulated container with frozen
130 gel packs and transported to the testing laboratory fridge within 12 hours.



131
 132 **Figure 1.** Vials of COVID-19 vaccine from Ontario, Canada: (A) Pfizer/BioNTech
 133 BNT162b2 adult monovalent and bivalent; Moderna Spikevax mRNA-1273 (B) adult
 134 monovalent XBB.1.5, (C) child/adult monovalent, (D) child/adult bivalent Wuhan-BA.1
 135 and (E) child/adult bivalent Wuhan-BA.1 and adult Wuhan-bivalent BA.4/5.

136
 137 **qPCR Analysis of Spike, ori, and the SV40 Promoter-Enhancer-ori DNA**
 138 Each vial was tested by quantitative PCR (qPCR) for the presence of plasmid derived
 139 SARS-CoV-2 spike, *ori*, and the SV40 promoter-enhancer-*ori* DNA. Spike and plasmid
 140 *ori* were tested in duplicate with PCR primers targeting sequences shared by the Moderna
 141 and Pfizer expression plasmids (Table 1). The uniplex SV40 Enhancer assay was
 142 designed to amplify the nuclear targeting sequence unique to the Pfizer vector⁶. In brief,
 143 the qPCR assays used 1 μ L from each vial directly added to 17.8 μ L of master mix. qPCR
 144 kits were sourced from Medicinal Genomics (Part# 420201, Beverly, USA) with the
 145 master mix containing 8.8 μ L reaction consisting of 3.8 μ L polymerase enzyme, 0.8 μ L
 146 reaction buffer and 1.0 μ L of Primer-Probe mix, and 12.2 μ L of ddH₂O. The Primer-Probe
 147 mix was assembled using 12.5 μ L 100 μ M *ori* probe, 12.5 μ L of 100 μ M spike probe, 25
 148 μ L of 100 μ M spike forward primer, 25 μ L of 100 μ M spike reverse primer, 25 μ L of 100
 149 μ M *ori* forward primer, 25 μ L 100 μ M *ori* reverse primer, and 75 μ L of ddH₂O.
 150

151 Spike and *ori* qPCR assays used a synthetic gDNA control (gBlock, Integrated DNA
 152 Technologies (IDT), San Diego, USA) of known concentration to generate a 10-fold serial
 153 dilution derived calibration curve. The SV40 enhancer gBlock failed initial synthesis and
 154 a standard curve could not be produced.

155

156 **Table 1.** Primer and probe sequences targeting spike, ori, and the SV40 promoter.

Primer-Probe Name	Sequence
MedGen-Moderna_Pfizer_Janssen_Vax-Spike_Forward	AGATGGCCTACCGTTCA
MedGen-Moderna_Pfizer_Janssen_Vax-Spike_Reverse	TCAGGCTGTCTGGATCTT
MedGen-Moderna_Pfizer_Janssen_Vax-Spike_Probe	/56-FAM/CGAGAACCA/ZEN/GAAGCTGATCGCCAA/3IAbkFQ/
MedGen_Vax-vector_Ori_Forward	CTACATACCTCGCTCTGCTAATC
MedGen_Vax-vector_Ori_Reverse	GCGCCTTATCCGGTAACTATC
MedGen_Vax-vector_Ori_Probe	/5HEX/AAGACACGA/ZEN/CTTATCGCCACTGGC/3IAbkFQ/
MedGen_SV40_Enhancer_Forward	GTCAGTTAGGGTGTGAAAGT
MedGen_SV40_Enhancer_Reverse	GGTTGCTGACTAATTGAGATGC
MedGen_SV40_Enhancer_Probe	/5TEX615/CCAGCAGGCAGAAGTATGCAAAGC/3IAbRQSp/

157

158

159 Cycling was performed on a QuantStudio 3 (ThermoFisher Scientific, Waltham, USA) with
 160 an initial denaturation of 95°C for 3 minutes followed by 35 cycles of 95°C for 10 seconds
 161 and 65°C for 30 seconds. Cq conversion to ng/ μ L was calculated using the QuantStudio
 162 software v2.7.0 (ThermoFisher Scientific). Amplicon mass, as determined with the New
 163 England BioLabs DNA calculator,⁷ and length (105 bp for *ori*, 114 bp for spike) were used
 164 to estimate the total nanograms (ng) of DNA present by adjusting for the length of the
 165 plasmids (7,824bp for Pfizer and 6,777bp for Moderna). Copy number per dose was
 166 adjusted for the volume of each intramuscular vaccine injection (300 μ L for Pfizer and
 167 500 μ L for Moderna). Serial dilutions were performed on the three Pfizer lots that showed
 168 the highest residual DNA concentration. to investigate PCR inhibition by the LNPs since
 169 qPCR was performed directly without any treatment or extraction.

170

171 ***Qubit® fluorometry quantitation***

172 AccuGreen® HS fluorometric reagents (AccuGreen #99820 and DNA Quantification
 173 Buffer #99979) and standards were acquired from Biotium (San Francisco, USA) for
 174 Qubit® analysis (ThermoFisher Scientific). Fluorometric reagents (190 μ L of a stock made
 175 from 995 μ L HS Buffer and 5 μ L 200X AccuGreen dye) were vortexed with 10 μ L of
 176 vaccine. These samples were heated to 95°C for 8 minutes and 4°C for 5 minutes to

177 disrupt the LNPs and enable Fluorometric Dyes to access the DNA. Samples were read
178 following the manufacturer's instructions on a Qubit 3.0 Fluorometer. Qubit fluorometry
179 and qPCR data were compared.

180

181 ***Vaccine Adverse Event Reporting System (VAERS) Data***

182 The VAERS database was analyzed using the Language and Environment for Statistical
183 Computing package in R,⁸ and included data spanning December 17, 2020 through
184 October 6, 2023. The VAERS data is available for download in three separate comma
185 separated values (csv) data files representing: i) general data for each report; ii) the
186 reported AEs or 'symptoms', and iii) vaccine data including vaccine manufacturer and lot
187 number.⁵ A VAERS ID number is assigned to preserve confidentiality when a report is
188 filed. To assess the AEs related to a particular vaccine, it is necessary to merge the three
189 data files using the VAERS IDs as a linking variable. For this study, since we are
190 interested in the COVID-19 products, only COVID-19 vaccine type (COVID19-1
191 (monovalent) and COVID19-2 (bivalent)) were included. Other relevant variables included
192 VAERS ID*, vaccine lot (VAX_LOT), vaccine manufacturer (VAX_MANU),
193 hospitalizations (HOSPITAL) and deaths (DIED). Data were grouped by vaccine lot and
194 the total number of AE and SAE reports were counted. SAE reports included deaths,
195 hospitalizations, emergency room visits, disability reports, birth defects and life-
196 threatening reports, and individual MedDRA coded AEs, such as total deaths per lot, were
197 also counted.

198

199 The various limitations of VAERS are widely acknowledged, for example by FDA⁹, and
200 include underreporting, misreporting, spontaneous reporting, and the inability to infer
201 causality. Nevertheless, to explore a possible dose-response relationship between
202 residual DNA content and SAEs, we used the ratio of the number of SAE reports to the
203 total number of AEs ("SAE reporting ratio" = SRR) as a proxy for a possible toxicological
204 effect. We used the total number of AEs reported by lot as a proxy for the total number of
205 doses administered, since this denominator is difficult to estimate. This principle is used
206 by the CDC in disproportionality signal analysis (DSA) to identify safety signals using the

207 Proportional Reporting Ratio (PRR)¹⁰ The PRR, as devised by Evans *et al.*, is a useful
208 tool in pharmacovigilance with known limitations.¹¹

209
210 It must be noted that although VAERS is a USA-based database, it accepts reports from
211 around the world. Certain categories of AEs that are reported to manufacturers outside
212 the USA, must be reported to the VAERS database. Differences in propensity for
213 underreporting as well as mandatory reporting imposed on manufacturers or medical
214 professionals within and outside the USA may introduce confounding to the estimation of
215 the SRR. Accordingly, for our exploratory dose-response analysis we only used VAERS
216 data originating outside the USA to reduce this confounding. Additionally, we have noted
217 some discrepancies in data obtained through the downloaded version of the VAERS
218 dataset, and those obtained using the VAERS WONDER front-end web-based interface
219 (<https://wonder.cdc.gov/controller/datarequest/D8>). We used the downloaded version as
220 it provides greater detail than the web version. The SRR was then plotted against levels
221 of DNA found in the vials to identify any association between residual DNA levels and the
222 frequency of reports of serious adverse events.

223
224 Where more than one vial was available in any lot, the average mass of residual DNA per
225 dose for that lot was used. Zero values of SRR for any given lot were only plotted if one
226 or more AEs had been identified worldwide, signifying that that lot had actually been
227 deployed. The curves were plotted on a logarithmic axis and a trend line drawn using the
228 linear function within Microsoft[®] Excel.

229

230 ***Oxford Nanopore Sequencing***

231 In a separate experiment using previously sequenced vaccine⁴ (Pfizer children's
232 monovalent Lot# FL8095), DNA fragment size distributions were estimated using an
233 Oxford Nanopore Flongle (R.10.4.1, Oxford Nanopore Technologies (ONT), New York,
234 USA) and the Oxford Nanopore Ligation sequencing kit (SQK-LSK114) according to the
235 manufacturer's instructions. Reads were mapped to NCBI OR134577.1 with the Burrow-
236 Wheeler Aligner with maximum exact matches (BWA-MEM).¹² ONT sequencing read

237 length is unlimited, but the DNA isolation procedures can bias the length of the molecules
238 captured in the ONT ligation reaction. Single molecule reads were counted and binned
239 according to their mapped read length with BWA-MEM.

240

241 ***Nuclease sensitivity of the vaccines***

242 The same vial (Pfizer Lot# FL8095) was used to assess DNaseI sensitivity of the vaccine
243 by determining if the DNA contamination is packaged in the LNP and thus resistant to
244 DNaseI or if the DNA resides outside of the LNP and is DNaseI labile.

245

246 Nuclease protected DNA was estimated by treating 20 μL of the vaccine with 2.5 μL of
247 DNaseI-XT (2 units/ μL , NEB#M0570S, New England BioLabs Inc, Ipswich, USA), 2.5 μL
248 of Grim Reefer 10X buffer (Medicinal Genomics #420123-125) and incubating at 37°C for
249 30 minutes. For the control, 2.5 μL of ddH₂O was used instead of the DNaseI-XT. The
250 DNaseI-XT reaction was chemically arrested using 2.5 μL of MGC lysis buffer (Medicinal
251 Genomics #420001). After the DNaseI chemical kill step, a qPCR amplifiable internal
252 control DNA was spiked-in to verify that the DNaseI-XT had been fully inactivated
253 (Medicinal Genomics #420123-125).

254


255 After spiking in the DNaseI inactivation control, 54 μL of SenSATIVAx magnetic beads
256 (Medicinal Genomics) were used to purify DNA from the DNaseI-XT assay and the
257 DNaseI-XT negative control samples. The magnetic beads were pipette mixed 10 times
258 with the sample, incubated at room temperature for 5 minutes, magnetically separated
259 and washed twice with 70% v/v ethanol. The ethanol was removed, and the beads dried
260 for 2 minutes at room temperature. Samples were eluted in 30 μL of ddH₂O and 1 μL of
261 eluate was examined by qPCR for spike and *ori* in an 18.8 μL reaction. An additional
262 DNaseI inactivation control primer and probe (0.5 μL in CY5) were added to the assay for
263 a total of 19.3 μL reaction.

264

265 **Results**

266 An 8-log serial dilution standard curve was used to calibrate sample C_q values and
267 generated R² values of 0.998 and 0.999 for spike and *ori* amplicons, respectively. PCR


268 efficiency was 99.8% and 94.7% for spike and *ori*, respectively (Figure 2). On all plates,
269 negative controls and no template (ddH₂O) controls (NTC) were tested in triplicate and
270 found to be negative.
271




272
273 **Figure 2.** Calibration curves of Spike (red) and *ori* (blue) diluted 10-fold and tested by
274 qPCR.

275 For individual vials, qPCR on Pfizer amplified at a similar time for spike, *ori*, and SV40
276 enhancer-promoter-*ori* (Δ Cq 1.48 ± 0.32) (Figure 3). Apart from Pfizer lot: FX4343, the
277 inter vial difference was small for both Pfizer (spike Cq 16.91 ± 0.52 ; *ori* Cq 16.91 ± 1.07 ;
278 SV40 promoter-enhancer-*ori* Cq 15.46 ± 2.02) and Moderna (spike Cq 20.35 ± 0.65 ; *ori*
279 Cq 25.34 ± 1.47) (values were based on the undiluted vials contents) (Table 2, Figure 4)
280

281 However, for all Moderna vials, except lot AS0467D, *ori* consistently amplified Cq 5-6
282 later than spike. The SV40 promoter-enhancer-*ori* was detected in all Pfizer vials but in
283 none of the Moderna vials.



284
 285 **Figure 3.** The amplification curve for spike (red), ori (blue), and SV40 enhancer-promoter-
 286 ori (green) in a single vial of Pfizer (Lot: Fx4343a) from two different wells of the same
 287 PCR run.



288


289 **Figure 4.** Amplification plot of all Pfizer (A) and Moderna (B) vials showing that spike (red)
 290 and ori (blue) amplified similarly for individual vials of Pfizer. In Moderna, inter-vial
 291 variability was consistent, but spike amplified earlier than ori ($\Delta Cq \sim 6$).

292 **Table 2.** Details of the vaccine vials, adverse events (AEs) identified, and qPCR testing results for SARS-CoV-2 spike, ori,
 293 and the SV40 promoter-enhancer-ori on all Pfizer-BioNTech and Moderna vials tested. Calculations for Pfizer and Moderna
 294 were based on adult doses of 0.30 mL and 0.50 mL, respectively. Moderna is also indicated to be given to children aged
 295 6-12 years of age with a dose of 0.25 mL making the resultant total ng/dose half of that given to adults. Total ng/dose is
 296 adjusted for the length of the amplicon (105 bp ori, 114 bp spike) only representing a fraction of the 7,824 bp Pfizer and
 297 6,777 bp Moderna plasmid.


Vaccine Information				VAERS Data		Spike			Ori			SV40 ^{§§}
Manufacturer	Type	Lot Number *	Printed Expiry Date	Total AES	Total SAEs	Cq	Total ng/dose	Total Copies/dose	Cq	Total ng/dose	Total Copies/dose	Cq
Pfizer-BioNTech	Adult Monovalent	FM7380	02/2022	29	15	18.03	2.43	2.07E+10	18.57	3.92	1.86E+11	17.19
Pfizer-BioNTech	Adult Monovalent	FN7934a	08/2022	42	21	18.47	1.79	1.53E+10	18.77	3.43	1.62E+11	16.64
Pfizer-BioNTech	Adult Monovalent	FN7934b	02/2022			18.19	2.18	1.86E+10	18.44	4.27	3.96E+10	16.96
Pfizer-BioNTech	Adult Monovalent	FX4343a	08/2022	1	0	23.53	0.27	2.30E+09	24.71	0.32	2.94E+09	20.64
Pfizer-BioNTech	Adult Monovalent	FX4343b	07/2022			23.83	0.22	1.86E+09	24.87	0.28	2.64E+09	22.59
Pfizer-BioNTech	Adult Bivalent	GK0932a	09/2022	3	0	20.46	2.25	1.92E+10	21.01	3.81	3.54E+10	18.53
Pfizer-BioNTech	Adult Bivalent	GK0932b	09/2022			20.60	2.05	1.75E+10	21.22	3.32	3.08E+10	18.91
Pfizer-BioNTech	Adult Bivalent	GK0932c	09/2022			20.66	1.97	1.68E+10	21.21	3.33	3.09E+10	18.6
Moderna	Child/Adult Monovalent	020E21A	None Stated	5	1	23.66	0.35	3.02E+09	29.47	0.02	1.87E+08	Neg
Moderna	Child/Adult Monovalent	020J21A	30/03/2022	7	5	23.21	0.48	4.12E+09	30.10	0.01	1.23E+08	Neg
Moderna	Child/Adult Monovalent	033M21Aa	22/06/2022	2	1	23.04	0.54	4.65E+09	29.46	0.02	1.88E+08	Neg
Moderna	Child/Adult Monovalent	033M21Ab	30/07/2022			22.81	0.64	5.44E+09	29.38	0.02	1.99E+08	Neg
Moderna	Child/Adult Monovalent	033M21Ac	30/03/2022			23.59	0.37	3.18E+09	29.87	0.02	1.43E+08	Neg
Moderna	Child/Adult Monovalent	033M21Ad	30/07/2022			23.26	0.47	3.98E+09	29.39	0.02	1.97E+08	Neg
Moderna	Child/Adult Monovalent	055K21A	30/07/2022	2	2	22.94	0.58	4.98E+09	29.58	0.02	1.74E+08	Neg
Moderna	Child/Adult Monovalent	062H21Aa	30/07/2022	9	3	22.52	0.78	6.69E+09	29.21	0.02	2.23E+08	Neg
Moderna	Child/Adult Monovalent	062H21Ab	28/05/2022			22.76	0.66	5.64E+09	29.37	0.02	2.00E+08	Neg
Moderna	Adult Bivalent BA.4/5	AT0709Ba	30/07/2023	0	0	23.68	0.35	2.99E+09	29.30	0.02	2.09E+08	Neg
Moderna	Adult Bivalent BA.4/5	AT0709Bb	30/07/2023			23.56	0.38	3.24E+09	29.25	0.02	2.16E+08	Neg
Moderna	Adult Bivalent BA.4/5	AT0709Bc	30/07/2023			23.63	0.36	3.09E+09	29.34	0.02	2.04E+08	Neg
Moderna	Adult Bivalent BA.4/5	AT0709Bd	30/07/2023			23.80	0.32	2.74E+09	29.44	0.02	1.91E+08	Neg
Moderna	Child/Adult Bivalent BA.1	AS0467Da	02/04/2023	0	0	23.20	0.49	4.17E+09	25.24	0.34	3.20E+09	Neg
Moderna	Child/Adult Bivalent BA.1	AS0467Db	02/04/2023			24.16	0.25	2.14E+09	26.08	0.20	1.82E+09	Neg
Moderna	Child/Adult Bivalent BA.1	AS0467Dc	02/04/2023			23.75	0.33	2.85E+09	25.74	0.25	2.28E+09	Neg
Moderna	Adult Monovalent XBB.1.5	020G23Aa	29/04/2024	0	0	24.42	0.73	6.26E+09	29.42	0.03	3.18E+08	Neg
Moderna	Adult Monovalent XBB.1.5	020G23Ab	29/04/2024			24.46	0.71	6.11E+09	29.87	0.03	2.33E+08	Neg
Moderna	Adult Monovalent XBB.1.5	020G23Ac	29/04/2024			24.53	0.68	5.84E+09	29.74	0.03	2.55E+08	Neg

298 *Lower case letters at the end of lot numbers indicate different vials of the same lot. ^{§§}SV40 promoter-enhancer-ori

299 DNA content in none of the Moderna and three Pfizer lots exceeded 1 ng/dose for either
 300 spike or plasmid *ori*. Vaccine in these three vials was diluted 10-fold serially to assess
 301 LNP inhibition in qPCR (Figure 5). We observed the expected ~3.3 Cq response after
 302 the 1:10 dilution (1:10, 1:100, 1:1000) suggesting that there is some LNP inhibition that
 303 could impact the quantitation of DNA at these dilutions (Figure 6). Therefore, the data
 304 from the 1:10 dilutions were used for further analysis. This dilution, as well as the fact
 305 that some of the doses were designed to be diluted before use, was accounted for in our
 306 calculations.



307
 308 **Figure 5.** Comparison of residual DNA content of spike (red) and *ori* (blue) and the total
 309 number of adverse events (orange) reported to VAERS. The FDA and WHO regulatory
 310 guideline of 10 ng/dose^{13 14} for residual DNA is shown by a red dotted line. Vials are
 311 sorted in descending order by DNA load of plasmid *ori*. Lower case letters at the end of
 312 lot numbers indicate different vials of the same lot. The total number of AEs was
 313 determined per lot and reproduced for each vial in the same lot.




314
 315 **Figure 6.** qPCR amplification profiles from the serial dilutions (10-fold) of the three lots
 316 containing the highest DNA loads (Pfizer lots: A, FN7934a; B, FN7934b; C, FM7380).

317
 318 The amount of residual DNA varied substantially between lots (0.28 - 4.27 ng/dose for
 319 Pfizer *ori*, 0.22 - 2.43 ng/dose for Pfizer spike, 0.01 - 0.34 ng/dose for Moderna *ori*, 0.25-
 320 0.78 ng/dose for Moderna spike) when tested by qPCR. Fluorometer based
 321 measurements (e.g., Qubit®) of the vaccines show 2,567 ± 618 ng/dose (range: 1,896
 322 to 3,720 ng/dose) for Pfizer and 4,280 ± 593 ng/dose (range: 3,270 to 5,100 ng/dose)
 323 for Moderna suggesting a high fraction of the DNA is under the size range of the qPCR
 324 amplicons.

325
 326 We plotted residual DNA values obtained by Qubit fluorometry against those obtained
 327 by qPCR (Figure 7). For the Pfizer product, the trend lines for *ori* and spike estimates
 328 both had a positive slope. The graph for the Moderna product differs from that of the
 329 Pfizer product with little overlap of values in either axis, with much shallower slopes.
 330 Although a detailed view of the Moderna plots suggests a negative slope for the *ori*


331 values, this trendline may be influenced by three outlying values. These values were
332 obtained from vials of the Moderna BA.1-Wuhan bivalent vaccines.
333



334
335 **Figure 7.** Graphical comparison of residual DNA concentration for spike (red) and ori
336 (blue) determined by qPCR and total residual DNA concentration in individual vials as
337 determined by Qubit. In panel A both Pfizer and Moderna data are plotted on the same
338 scale. The Moderna data are enclosed in a red box and displayed separately with an
339 enlarged scale in panel B, to display detail.


340
341 Other than Moderna lots AS0709D, AS0467D and 020G23A, VAERS reports were found
342 for all lots examined in this study (Figure 5). Of the 12 lots examined, the lots with the
343 highest numbers of reports filed to VAERS worldwide were FM7380 and FN7934 with
344 29 and 42 reports, respectively. In the case of lot FM7380, 15 individuals (52%) reported
345 an SAE, whereas for lot FN7934, 1 individual died, 2 individuals reported a disability,
346 and 18 reported being hospitalized with 21 (50%) SAEs. There were 9, 7, 5, 3, 2, and 2
347 reports filed for lots 062H21A, 020J21A, 020E21A, GK0932, 033M21A and 055K21A,
348 respectively. Of these lots, 5/7 (71%) reports for Moderna lot 020J21A involved
349 hospitalization, and there were 1/5 reports of death for Moderna lot 020E21A. In total
350 there were 100 reports of AEs filed worldwide to VAERS for these lots; 48 (48%) of these
351 were SAEs. Most of these AE (n=92) and SAE (n=44) reports originated from outside
352 the USA in similar proportion. Of these 92 AEs, 70 (76%) could be identified as
353 originating in Canada, with another 5 (5.4%) whose origin could not be determined.
354

355 In an exploratory analysis, we constructed dose-response curves by plotting (Figure 8)
 356 the mass of DNA for spike (red) and plasmid *ori* (blue) found in Pfizer (upper panel) and
 357 Moderna (lower panel) vials against the SAE reporting ratio (SRR). The *ori* and spike
 358 curves for the Pfizer product are similar to each other and show a positive dose-response
 359 relationship. The corresponding curves for the Moderna lots are shifted leftwards by one
 360 to two orders of magnitude. However, the *ori* and spike curves differ in position and
 361 slope.




362
 363 **Figure 8.** Exploratory dose-response analysis comparing the concentration of residual
 364 DNA measured by qPCR for spike (red) and plasmid *ori* (blue) found in Pfizer (A) and
 365 Moderna (B) lots plotted against the SRR (reports of SAEs / total number of all adverse
 366 events reported to VAERS) for each lot from countries outside of the USA. Residual
 367 DNA mass per dose is plotted on a logarithmic scale. Data from the 1:10 dilution were
 368 used.

369 The corresponding plots for residual DNA estimated using fluorometry (Figure 9) yielded
370 curves with a negative slope for both the Pfizer and Moderna products.
371




372
373 **Figure 9.** Exploratory dose-response analysis comparing the concentration of residual
374 DNA measured by Qubit fluorometry for Pfizer (blue) and Moderna (red) vaccine lots
375 plotted against the SRR (reports of SAEs / total number of all adverse events reported
376 to VAERS) from countries outside of the USA. Residual DNA mass per dose is plotted
377 on a logarithmic scale.

378
379 The Pfizer children's monovalent (Lot FL8095) described by McKernan *et al.*⁴ was
380 sequenced with Oxford Nanopore (ONT) to assess the read length distributions after
381 mapping the reads to the reference sequence of the plasmid in NCBI (Figure 8). The
382 longest read detected in 865 reads was 3.5 kb with read mapping to most of the plasmid
383 backbone (Figure 9).



384

385 **Figure 10.** Oxford Nanopore (ONT) read length distributions from 866 reads mapped to
 386 the vector sequence (NCBI OR134577.1). Mean = 214 bp. Max = 3.5 kb.




387

388 **Figure 11.** Longest Oxford Nanopore (ONT) read aligns to the vector region shown in
 389 blue. ori and spike primer locations are annotated on the innermost circle. Open reading
 390 frames (ORFs) are annotated in gold and green arrows. Kanamycin resistance genes
 391 were detected in a very shallow sequencing survey of the vaccine.

392 Nuclease sensitivity of the Pfizer vaccine was assessed using DNaseI-XT. This DNA
 393 nuclease is optimized for IVT reactions rich in RNA:DNA hybrids. This treatment showed
 394 ≤ 1 Cq offset while a naked DNA control spiked into LNPs was reduced from a Cq of 15
 395 to undetectable under the same conditions. This indicates that the DNA present in the
 396 vaccines is protected by encapsulation in the LNPs (Figure 10, Figure 11).


Significant fractions of the LNPs are DNaseI protected
 This implies 10-30% of the nucleic acid isn't packaged in an LNP



397 1 CT offset in DNase treatment = half of the nucleic acid being unpackaged.

398 **Figure 12.** DNase I-XT treatment of Pfizer vaccine demonstrates nuclease resistance
 399 of the DNA in the vaccines.

Grim Reefer method eliminates all DNA at 37°C in 30 minutes.
 2ul in qPCR of a 1:10 dilution of GR control = 15CT
 LNPs protect against this activity.



400 **Figure 13.** DNaseI-XT positive control demonstrates the digestion assay eliminates all
 401 spiked in DNA under the same conditions used to assess the vaccine nuclease
 402 sensitivity.
 403

404 **Discussion**

405 Residual DNA was detected in all 27 vaccine vials surveyed. Multiple vials from the same
406 lots produced very similar loads for all targets showing assay reliability, reproducibility,
407 and consistency within the lots. These data involving vaccine vials distributed in Canada
408 are consistent with several non-peer reviewed reports of DNA contamination in modRNA
409 vaccines (McKernan, Buckhaults, Konig).^{4 15 16}

410

411 Moderna had the lowest DNA concentration by qPCR but the highest concentration with
412 Qubit. The Moderna vials had the most consistent levels of DNA between vials
413 suggesting a more robust and standardized manufacturing process. In each vial of the
414 Moderna product, except for lot AS0467D, *ori* displayed lower loads than spike
415 suggesting a more effective removal of the vector DNA. Possibly, homologous modified
416 RNA may prevent digestion of template DNA by hybridization.¹⁷

417

418 The vials with the highest DNA concentration were from two lots of Pfizer monovalent
419 purple top vials with a phosphate buffered saline (PBS) formulation and require dilution
420 before administration. On October 29, 2021, the US FDA authorized a change of
421 formulation to a Tris/sucrose buffer; the grey topped monovalent adult vaccine and an
422 orange topped vaccine for children aged 6-11 years, This change was made to increase
423 stability, to simplify storage requirements and to provide a ready-to-use formulation.^{18 19}
424 These purple-topped Pfizer lots were also associated with the highest number of AEs
425 and SAEs reported in VAERS among all the lots tested. As the actual number of doses
426 administered for each lot is unknown, we used the total number of AEs as a proxy for
427 the number of doses administered as a denominator for the number of SAEs to estimate
428 toxicologic/pharmacologic effect. This uses the same principle used by CDC^{10 11} in its
429 disproportionality signal analysis (DSA).

430

431 Our exploratory analysis of the relationship between the residual DNA content and SAEs
432 reported to VAERS is preliminary and limited in sample size but warrants confirmation
433 by examining many more lots and vials. A positive dose-response relationship was
434 observed for the Pfizer lots based on qPCR estimation of residual DNA.

435 Different relationships were observed for Moderna lots for qPCR data as well as for plots
436 based on residual DNA estimated by fluorometry, for both Pfizer and Moderna lots.
437 These observations may reflect differences between the two products such as quantity
438 of DNA, the size distribution of DNA fragments, the composition and sequence of the
439 plasmid vector and composition of lipid nanoparticles. Other differences both between
440 the two products and between different lots of each product may also contribute to our
441 observations. These differences include variations in levels of contaminants or
442 impurities. One major source of impurity is fragmented mRNA for which a number of
443 toxicological mechanisms have been proposed such as its effects on miRNA
444 processes.²⁰ dsRNA is another type of impurity that occurs secondarily to the T7 RNA
445 polymerase promoter. dsRNA can induce pro-inflammatory cytokines²¹ and has been
446 hypothesized to contribute to immune-inflammatory reactions such as myocarditis.²²
447 Lipopolysaccharides in cells from endotoxin can bind both the S1 and S2 subunits of the
448 spike protein which may result in enhanced inflammatory responses.²³

449

450 Wider sampling will likely reveal greater detail in terms of event types, such as death, as
451 well as comparisons with other works such as that reported by Schmeling *et al.*²⁴ who
452 reported a correlation of AEs to various vaccine lot numbers²⁴. None of the presently
453 studied vaccine lots were included in the Schmeling study and more work is needed to
454 understand if and how this DNA contamination is related to AEs.

455

456 While the SV40 enhancer facilitates nuclear localization,^{6,25} genomic integration of DNA
457 fragments has yet to be demonstrated for the COVID-19 modRNA products.²⁶ However,
458 it is known that DNA contamination could trigger an unwarranted innate immune
459 response and may be prothrombotic, particularly for fragments with high GC content.²⁷
460 dsDNA may also be a significant factor in ischemic diseases including stroke.²⁸ While
461 there appears to be a correlation between high DNA contamination and SAEs more
462 research is needed to expand the sample size and elucidate any potential mechanism
463 at work.

464

465 It is important to emphasize that because qPCR cannot quantitate molecules smaller
466 than the size of the amplicon (105-114 bp), qPCR underestimates the total DNA in each
467 vaccine. This explains the large differences we have observed in residual DNA levels
468 estimated by qPCR compared with Qubit fluorometry particularly between the Pfizer and
469 Moderna products. The much larger values obtained for the Moderna product suggests
470 that there is a higher fraction of small fragmented residual DNA than in the Pfizer
471 product. This is consistent with a more thorough nuclease digestion step. This illustrates
472 the DNA contamination guidelines recommended by the FDA are highly dependent on
473 the methods used to quantitate the DNA. An alternative hypothesis to explain the high
474 fluorometric measurements is the unknown specificity of the DNA-tropic fluorometric
475 dyes when in use with samples that have high concentrations of N1-methyl-
476 pseudouridine modRNA.

477

478 This fluorometry assessment is of particular interest as fluorometry and UV
479 spectrophotometry were used to quantitate RNA in the Pfizer COVID-19 vaccines, as
480 described in EMA documents³, while qPCR was used to quantitate DNA. This selective
481 use of different methods to quantitate RNA/DNA ratios can lead to vastly different results
482 for the ratio-metric guidelines in place at the EMA.

483

484 This elevated fluorometry quantitation compared to qPCR quantitation is consistent with
485 the ONT read length distributions that also suggest a portion of the DNA may be smaller
486 than the amplicon size. While the ONT sequencer detects molecules shorter than 100
487 bp, the methods for library construction for ONT use a 0.7X Ampure DNA purification
488 step which drastically selects against purifying molecules <150 bp in size. As a result,
489 the read length distributions for ONT reads are biased towards fragments >150 bp and
490 are not a perfect reflection of the smaller fragments that may be present and
491 undercounted by both ONT and qPCR.

492

493 Currently, the US FDA recommends manufacturers of viral vaccines to limit the amount
494 of residual DNA in the final product to below 10 ng/dose for parenteral inoculations and
495 the size of the DNA to below the size of a functional gene, or ~200 base pairs.¹³ This is

496 also in keeping with recommendations from the World Health Organization (WHO).^{14 29}
497 Previous residual DNA levels were set by the FDA at 10pg/dose in 1985. A 1986 WHO
498 study group concluded that the risk is negligible up to 100 pg/dose and in 1996 the WHO
499 further increased levels up to 10 ng per dose.¹⁴

500

501 The FDA and WHO guidelines for allowable DNA in vaccines are influenced by work
502 published by FDA scientists Sheng-Fowler *et al.*³⁰ This work focused on host cell
503 genomic DNA contamination and made note of the increased number of molecules
504 present when small viral vectors are the contaminating species. For these high copy per
505 nanogram contaminants, femtograms to attograms of DNA are considered the
506 equivalent of nanograms of cell substrate genomic DNA. Given the short fragment size
507 in the modRNA vaccines, the number of molecules in each dose can reach over 100
508 billion molecules. The residual DNA in these vaccines is high in copy number and rich
509 in promoters, ORFs and nuclear targeting sequences. The FDA and WHO guidelines
510 did not consider packaging of DNA in lipid nanoparticles, likely resulting in longer DNA
511 persistence as well as increased transfection efficiency. Furthermore, the guidelines did
512 not consider cumulative dosing with LNP-based modRNA. In some cases, more than
513 five doses of COVID-19 vaccines have been administered with a dose interval for
514 booster doses sometimes as short as 2 months. Moreover, the risks of cumulative dosing
515 by vaccines targeting other infections but using the same plasmid and LNP-based
516 modRNA platform has not been considered in setting the residual DNA guidelines.

517

518 The FDA guidelines are also written to only quantitate DNA fragments of 200 bp or
519 greater, in part because fragments smaller than this were not considered to be able to
520 produce a functional gene. However, Klinman *et al.*,³¹ suggests that fragments as small
521 as 7bp can pose integration risks. Furthermore, the guidelines may also have considered
522 that fragments of naked DNA shorter than 200 bp would be more rapidly hydrolyzed by
523 host nucleases activity than larger molecules.³² This accelerated destruction cannot be
524 assumed of the vaccines due to the DNA being encapsulated and protected by the LNPs.

525

526

527 Klinman *et al.*,³¹ also observe that *“in evaluating the potential harm of plasmid*
528 *integration, it should be noted that the risk of introducing plasmids with strong regulatory*
529 *regions into the host genome far exceeds that associated with random point mutations.”*

530

531 Finally, the guidelines do not consider if the residual DNA contains nuclear targeting
532 sequences and mammalian promoters that exist in the Pfizer vaccine.²⁶ Vacik *et al.*
533 demonstrated that the SV40 enhancer present in the Pfizer vector is a potent nuclear
534 targeting sequence showing promise for gene therapy.²⁵

535

536 **Conclusion**

537 These data demonstrate the presence of billions to hundreds of billions of DNA
538 molecules per dose in the modRNA COVID-19 products tested. Using fluorometry, all
539 products tested exceeded the guidelines for residual DNA set by the FDA and WHO of
540 10 ng/dose by 188 – 509-fold. However, qPCR detected residual DNA content in all
541 products tested were below these guidelines emphasizing the importance of
542 methodological clarity and consistency when interpreting quantitative guidelines. The Cq
543 scores for the most recent XBB.1.5 Moderna vaccine suggest that DNA residues have
544 not been reduced from previous vaccine versions.

545

546 The preliminary evidence of a dose-response effect of residual DNA measured with
547 qPCR and SAEs warrants confirmation and further investigation. Our findings extend
548 existing concerns about vaccine safety and call into question the relevance of guidelines
549 conceived before the introduction of efficient transfection using LNPs. With several
550 obvious limitations, we urge that our work is replicated under forensic conditions and
551 that guidelines be revised to account for highly efficient DNA transfection and cumulative
552 dosing.

553

554 This work highlights the need for regulators and industry to adhere to the precautionary
555 principle, and provide sufficient and transparent evidence that products are safe and
556 effective, and disclose the details of their composition and method of manufacture.

557

558 **Data Availability**

559 Fastq file for the mapped ONT sequencing data:

560 <https://mega.nz/file/UZhkiTBQ#8vjDK5JV5N5Dj2On34B6zdRObEKGBY3ZC7w8q2t9U>

561 [Vc](#)

562

563 **Acknowledgements**

564 We thank all the pharmacists who donated to our endeavors.

565

566 **Author Contributions**

567 **DJ Speicher:** sample management, study design, qPCR, data analysis, manuscript
568 preparation

569 **J Rose:** VAERS analysis, manuscript preparation

570 **LM Gutschi:** data analysis, manuscript preparations

571 **D Wiseman:** data analysis, manuscript preparations

572 **K McKernan:** qPCR assay design, DNaseI and ONT experiments, manuscript
573 preparation

574

575 **Conflict of Interest Statement**

576 Kevin McKernan is employed by Medicinal Genomics and provided qPCR reagents free
577 of charge. The other authors declare that there are no conflicts of interest.

578

579 **Revision History**

580 2023-10-19 – version 1.0

581 **References**

- 582 1. Guetzkow JA. Letters to the editor: Effect of mRNA Vaccine Manufacturing Processes
583 on Efficacy and Safety Still an Open Question. *BMJ* 2023;378:o1731.
- 584 2. Tinari S. The EMA covid-19 data leak, and what it tells us about mRNA instability.
585 *BMJ* 2021;372:n627. doi: 10.1136/bmj.n627 [published Online First: 20210310]
- 586 3. EMEA/H/C/005735/RR. Rapporteur Rolling Review Critical Assessment Report:
587 Quality Aspects. 2020 [Available from: [https://covidvaccinereactions.com/ema-](https://covidvaccinereactions.com/ema-pfizer-leak/)
588 [pfizer-leak/](https://covidvaccinereactions.com/ema-pfizer-leak/)].
- 589 4. McKernan K, Helbert Y, Kane LT, et al. Sequencing of bivalent Moderna and Pfizer
590 mRNA vaccines reveals nanogram to microgram quantities of expression vector
591 dsDNA per dose. *OSFio* 2023 doi: 10.31219/osf.io/b9t7m
- 592 5. Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse
593 Event Reporting System (VAERS). *Vaccine* 2015;33(36):4398-405. doi:
594 10.1016/j.vaccine.2015.07.035 [published Online First: 20150722]
- 595 6. Dean DA, Dean BS, Muller S, et al. Sequence requirements for plasmid nuclear
596 import. *Exp Cell Res* 1999;253(2):713-22. doi: 10.1006/excr.1999.4716
- 597 7. New England Biolabs. NEBioCalculator 2023 [Available from:
598 <https://nebiocalculator.neb.com/#/!dsdnaamt2023>].
- 599 8. R: The R Project for Statistical Computing [program]: R Foundation for Statistical
600 Computing, 2010.
- 601 9. Funk PR, Yogurtcu ON, Forshee RA, et al. Benefit-risk assessment of COVID-19
602 vaccine, mRNA (Comirnaty) for age 16-29 years. *Vaccine* 2022;40(19):2781-89.
603 doi: 10.1016/j.vaccine.2022.03.030 [published Online First: 20220328]

- 604 10. VAERS Team. Vaccine Adverse Event Reporting System (VAERS) Standard
605 Operating Procedures for COVID-19 (as of 29 January 2021) 2021 [Available from:
606 <https://www.cdc.gov/vaccinesafety/pdf/VAERS-v2-SOP.pdf>.
- 607 11. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal
608 generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol*
609 *Drug Saf* 2001;10(6):483-6. doi: 10.1002/pds.677
- 610 12. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
611 transform. *Bioinformatics* 2009;25(14):1754-60. doi:
612 10.1093/bioinformatics/btp324 [published Online First: 20090518]
- 613 13. Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC)
614 Information for Human Gene Therapy Investigational New Drug Applications
615 (INDs): U.S. Department of Health and Human Services; 2020 [Available from:
616 <https://www.fda.gov/media/113760/download>.
- 617 14. Shin J, Wood D, Robertson J, et al. WHO informal consultation on the application of
618 molecular methods to assure the quality, safety and efficacy of vaccines, Geneva,
619 Switzerland, 7-8 April 2005. *Biologicals* 2007;35(1):63-71. doi:
620 10.1016/j.biologicals.2005.12.005 [published Online First: 20060220]
- 621 15. South Carolina Senate. SC Senate Hearing - USC Professor Dr. Phillip Buckhaults
622 2023 [updated 2023-09-13. Available from:
623 <https://www.youtube.com/watch?v=IEWHhrHiiTY>.
- 624 16. Koning B. Letter regarding the evidence presented to you of massive DNA
625 contamination in BioNTech's COVID-19 mRNA vaccine.
626 [https://www.genimpfstoffe.com/wp-content/uploads/2023/09/Verblindet-Fax-](https://www.genimpfstoffe.com/wp-content/uploads/2023/09/Verblindet-Fax-BMG-Lauterbach-16.-Sept-2023-1.pdf)
627 [BMG-Lauterbach-16.-Sept-2023-1.pdf](https://www.genimpfstoffe.com/wp-content/uploads/2023/09/Verblindet-Fax-BMG-Lauterbach-16.-Sept-2023-1.pdf), 2023.
- 628 17. Sutton DH, Conn GL, Brown T, et al. The dependence of DNase I activity on the
629 conformation of oligodeoxynucleotides. *Biochem J* 1997;321 (Pt 2)(Pt 2):481-6.
630 doi: 10.1042/bj3210481

- 631 18. U.S. Food and Drug Administration. Emergency Use Authorization (EUA) for an
632 Unapproved Product Review Memorandum 2021 [Available from:
633 <https://www.fda.gov/media/153947/download>.
- 634 19. Food and Drug Administration. Letter of Authorization 2023 [Available from:
635 <https://www.fda.gov/media/150386/download>.
- 636 20. Stati G, Amerio P, Nubile M, et al. Concern about the Effectiveness of mRNA
637 Vaccination Technology and Its Long-Term Safety: Potential Interference on
638 miRNA Machinery. *Int J Mol Sci* 2023;24(2) doi: 10.3390/ijms24021404 [published
639 Online First: 20230111]
- 640 21. Nelson J, Sorensen EW, Mintri S, et al. Impact of mRNA chemistry and
641 manufacturing process on innate immune activation. *Sci Adv*
642 2020;6(26):eaaz6893. doi: 10.1126/sciadv.aaz6893 [published Online First:
643 20200624]
- 644 22. Milano G, Gal J, Creisson A, et al. Myocarditis and COVID-19 mRNA vaccines: a
645 mechanistic hypothesis involving dsRNA. *Future Virol* 2021 doi: 10.2217/fvl-2021-
646 0280 [published Online First: 20211206]
- 647 23. Samsudin F, Raghuvamsi P, Petruk G, et al. SARS-CoV-2 spike protein as a
648 bacterial lipopolysaccharide delivery system in an overzealous inflammatory
649 cascade. *J Mol Cell Biol* 2023;14(9) doi: 10.1093/jmcb/mjac058
- 650 24. Schmeling M, Manniche V, Hansen PR. Batch-dependent safety of the BNT162b2
651 mRNA COVID-19 vaccine. *Eur J Clin Invest* 2023;53(8):e13998. doi:
652 10.1111/eci.13998 [published Online First: 20230409]
- 653 25. Vacik J, Dean BS, Zimmer WE, et al. Cell-specific nuclear import of plasmid DNA.
654 *Gene Ther* 1999;6(6):1006-14. doi: 10.1038/sj.gt.3300924

- 655 26. Lim S, Yocum RR, Silver PA, et al. High spontaneous integration rates of end-
656 modified linear DNAs upon mammalian cell transfection. *Sci Rep* 2023;13(1):6835.
657 doi: 10.1038/s41598-023-33862-0 [published Online First: 20230426]
- 658 27. Gaitzsch E, Czermak T, Ribeiro A, et al. Double-stranded DNA induces a
659 prothrombotic phenotype in the vascular endothelium. *Sci Rep* 2017;7(1):1112.
660 doi: 10.1038/s41598-017-01148-x [published Online First: 20170425]
- 661 28. Ma X, Xin D, She R, et al. Novel insight into cGAS-STING pathway in ischemic
662 stroke: from pre- to post-disease. *Frontiers in Immunology* 2023;14
- 663 29. World Health Organization. Annex 3: Requirements for the use of animal cell cultures
664 as substrates for the manufacture of biologic medicinal products and the
665 characterization of cell banks. Replacement of Annex 1 of WHO Technical Report
666 Series, No. 878. 2013 [Available from: [https://cdn.who.int/media/docs/default-
667 source/biologicals/documents/trs_978_annex_3.pdf?sfvrsn=fe61af77_3&downloa
668 d=true](https://cdn.who.int/media/docs/default-source/biologicals/documents/trs_978_annex_3.pdf?sfvrsn=fe61af77_3&download=true)].
- 669 30. Sheng-Fowler L, Lewis AM, Jr., Peden K. Issues associated with residual cell-
670 substrate DNA in viral vaccines. *Biologicals* 2009;37(3):190-5. doi:
671 10.1016/j.biologicals.2009.02.015 [published Online First: 20090314]
- 672 31. Klinman DM, Klaschik S, Tross D, et al. FDA guidance on prophylactic DNA
673 vaccines: analysis and recommendations. *Vaccine* 2010;28(16):2801-5. doi:
674 10.1016/j.vaccine.2009.11.025 [published Online First: 20091124]
- 675 32. André M, Reghin S, Boussard E, et al. Universal real-time PCR assay for quantitation
676 and size evaluation of residual cell DNA in human viral vaccines. *Biologicals*
677 2016;44(3):139-49. doi: 10.1016/j.biologicals.2016.03.002 [published Online First:
678 20160328]
679

